| |
HCV DAA Costs & Use Gilead Millman Report
|
| |
| |
Download the PDF here
This report discusses the reduction in cost per treatment regimen from $84,000 in 2013 to an average net cost of approximately $11,500 to $17,0001 in mid-2020, based on available data across key segments and products.
MILLIMAN WHITE PAPER
Analysis of prescription drugs for the treatment of hepatitis C in the United States 1 May 2021
A study of the evolution of second-generation direct-acting antivirals to treat hepatitis C virus from mid-
2014 to mid-2020
Commissioned by Gilead Sciences, Inc.
| |
| |
| |
|
|
|
